Single-Photon Emission Computed Tomography (SPECT) Market Report 2026

Single-Photon Emission Computed Tomography (SPECT) Market Overview

• Single-Photon Emission Computed Tomography (SPECT) market size has reached to $2.5 billion in 2025 • Expected to grow to $3.92 billion in 2030 at a compound annual growth rate (CAGR) of 9.5% • Growth Driver: Rising Cancer Prevalence Driving The Single-Photon Emission Computed Tomography (SPECT) Market • Market Trend: Innovative Ventures With Portable Gamma Cameras Transforming The Single-Photon Emission Computed Tomography (SPECT) Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Single-Photon Emission Computed Tomography (SPECT) Market?

Single-photon emission computed tomography (SPECT) is a medical imaging technique that uses radioactive tracers and gamma rays to produce 3D images of internal organs and tissues. The tracer can be detected by a gamma camera by emitting gamma rays, allowing for non-invasive and detailed imaging of a patient's internal structure. The main types of single-photon emission computed tomography (SPECT) systems are hybrid and standalone SPECT systems. Hybrid SPECT systems refer to a medical imaging device that combines functional and anatomical information obtained from SPECT and CT or MRI and provides more accurate diagnoses. Various radioisotopes involved in SPECT systems include Tc-99m, Ra-223, Ga-67, I-123, and other radioisotopes in a variety of applications such as oncology, cardiology, neurology, and other applications by hospitals, diagnostic centers, and other end users.

What Is The Single-Photon Emission Computed Tomography (SPECT) Market Growth Forecast?

The single-photon emission computed tomography (spect) market size is expected to see strong growth in the next few years. It will grow to $3.92 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing demand for advanced molecular imaging, rising adoption of precision diagnostics, expansion of outpatient diagnostic centers, growing integration of AI in medical imaging, increasing focus on early disease detection. Major trends in the forecast period include increasing adoption of hybrid spect imaging systems, rising use of ai-assisted image reconstruction, growing demand for cardiac and oncology imaging, expansion of multi-head gamma camera systems, enhanced focus on diagnostic accuracy.

Global Single-Photon Emission Computed Tomography (SPECT) Market Segmentation

1) By Type: Hybrid SPECT Systems, Standalone SPECT Systems 2) By Type Of Radioisotopes: Tc-99m, Ra-223, Ga-67, I-123, Other Radioisotopes 3) By Application: Oncology, Cardiology, Neurology, Other Applications 4) By End User: Hospitals, Diagnostic Centers, Other End User Subsegments: 1) By Hybrid SPECT Systems: SPECT Or CT Systems, SPECT Or MRI Systems 2) By Standalone SPECT Systems: Single-Head SPECT Systems, Multi-Head SPECT Systems

What Is The Driver Of The Single-Photon Emission Computed Tomography (SPECT) Market?

The rise in the prevalence of cases of cancer is expected to propel the growth of the single-photon emission computed tomography (SPECT) market going forward. This rise in the number of cancer cases has resulted from a rise in the aging population, unhealthy lifestyle choices, and environmental factors. Single-photon emission computed tomography (SPECT) helps in the diagnosis, staging, and monitoring of cancer along with other imaging techniques like computed tomography (CT) and Magnetic Resonance Imaging (MRI) scans. For instance, in 2023, according to Cancer Australia, an Australia-based government agency, approximately 8,257 new cases of melanoma of the skin were diagnosed, accounting for 2.6% of all deaths from cancer. Therefore, the rise in the prevalence of cases of cancer is driving the growth of the single-photon emission computed tomography (SPECT) industry.

Key Players In The Global Single-Photon Emission Computed Tomography (SPECT) Market

Major companies operating in the single-photon emission computed tomography (spect) market are GE Healthcare Technologies Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Canon Medical Systems Corporation, United Imaging Healthcare Co. Ltd., Mediso Ltd., Spectrum Dynamics Medical Inc., Digirad Corporation, Gamma Medica Inc., Neusoft Medical Systems Co. Ltd., Trasis S.A., Curium Pharma, Lantheus Holdings Inc., Bracco Imaging S.p.A., Guerbet S.A., Eckert & Ziegler AG, Nordion Inc., Bayer AG, Advanced Accelerator Applications, Ion Beam Applications S.A., Hitachi Ltd.

Global Single-Photon Emission Computed Tomography (SPECT) Market Trends and Insights

Major companies operating in Single-photon emission computed tomography (SPECT) are developing innovative products, such as portable gamma cameras, to drive the revenues in the market. Portable gamma cameras refer to compact, mobile nuclear imaging devices used to detect gamma radiation emitted from radiopharmaceuticals inside the body. For instance, in June 2023, Serac Imaging, a UK-based molecular imaging company, launched a portable high-resolution hybrid gamma optical camera. The device is designed to be complementary to the technology currently used in nuclear medicine departments and aims to simplify workflows and bring additional capacity.

What Are Latest Mergers And Acquisitions In The Single-Photon Emission Computed Tomography (SPECT) Market?

In April 2025, GE HealthCare Technologies, Inc., a US-based diagnostics company, acquired the remaining 50% stake in Nihon Medi-Physics Co., Ltd. from Sumitomo Chemical for an undisclosed amount. With this acquisition, GE HealthCare aimed to secure full ownership of a leading Japanese radiopharmaceutical company to further scale its molecular-imaging business, expand its therapeutic diagnostics capabilities, and deepen its presence in the growing nuclear medicine market. Nihon Medi-Physics Co. Ltd. is a Japan-based pharmaceutical-diagnostics company that specializes in developing and manufacturing proprietary and in-licensed radiopharmaceuticals for SPECT and PET molecular imaging.

Regional Outlook

North America was the largest region in the single-photon emission computed tomography (SPECT) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the single-photon emission computed tomography (SPECT) market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Single-Photon Emission Computed Tomography (SPECT) Market?

The single-photon emission computed tomography (SPECT) market consists of the sale of SPECT/CT and of Single Imaging Gamma Cameras. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.